M. Mérienne

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke

Pierre Amarenco, Jong S. Kim, Julien Labreuche et al. · Stroke · 2020 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Association of class II HLA-D ? chain DNA restriction fragments with multiple sclerosis

A. Marcadet, Catherine Massart, G. Sémana et al. · Immunogenetics · 1985 · 50 citations

Life Sciences, Immunology, Neurology +16

Intracranial Hemorrhage in the TST Trial

Pierre Amarenco, Julien Labreuche, Maurice Giroud et al. · Stroke · 2021 · 25 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

María Trojano, Helmut Butzkueven, Ludwig Kappos et al. · Multiple Sclerosis and Related Disorders · 2018 · 19 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Register‐based incidence of multiple sclerosis in Brittany (north‐western France), 2000–2001

Jacqueline Yaouanq, Isabelle Tron, Anne Kerbrat et al. · Acta Neurologica Scandinavica · 2014 · 15 citations · Full text

Medicine, Neurology, Clinical Epidemiology +9